Regeneron Pharmaceuticals Inc
$
333.34
-9.63 (-2.81%)
| Volume: | 1,920,372 | Avg Vol (1m): | 736,032 |
| Market Cap $: | 36.43 Bil | Enterprise Value $: | 34.33 Bil |
| P/E (TTM): | 15.65 | P/B: | 4.15 |
| Earnings Power Value | 97.68 |
| Net Current Asset Value | 31.84 |
| Tangible Book | 80.34 |
| Projected FCF | 175.85 |
| Median P/S Value | 575.9 |
| Graham Number | 196.22 |
| Peter Lynch Value | 532.5 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 8/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 3.97 | ||
| Equity-to-Asset | 0.75 | ||
| Debt-to-Equity | 0.08 | ||
| Debt-to-EBITDA | 0.26 | ||
| Interest Coverage | 89.87 | ||
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 9.78 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.24 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 39.99%
WACC 9.26%
| ||
Profitability & Growth : 8/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 37.77 | ||
| Net Margin % | 36.42 | ||
| ROE % | 33.46 | ||
| ROA % | 24.14 | ||
| ROC (Joel Greenblatt) % | 59.04 | ||
| 3-Year Total Revenue Growth Rate | 17.80 | ||
| 3-Year Total EBITDA Growth Rate | 27.60 | ||
| 3-Year EPS w/o NRI Growth Rate | 56.80 |
» REGN's 30-Y Financials
Financials (Next Earnings Date: 2019-05-07)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:REGN
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | XKRX:068270 XKRX:207940 NAS:VRTX NAS:ALXN HKSE:01177 LSE:SHP XMCE:GRF.P NAS:BMRN XBRU:UCB NAS:NKTR OCSE:NZYM B NAS:INCY OCSE:GEN NAS:BIVV HKSE:02269 NAS:JUNO NAS:ALNY NAS:BGNE NAS:JAZZ NAS:BIIB |
| Traded in other countries | RGO.Germany 0R2M.UK |
| Address | 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707 |
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 15.65 | ||
| Forward PE Ratio | 14.37 | N/A | |
| PE Ratio without NRI | 15.65 | ||
| Price-to-Owner-Earnings | 27.36 | ||
| PB Ratio | 4.15 | ||
| PS Ratio | 5.70 | ||
| Price-to-Free-Cash-Flow | 21.12 | ||
| Price-to-Operating-Cash-Flow | 17.43 | ||
| EV-to-EBIT | 13.30 | ||
| EV-to-EBITDA | 12.57 | ||
| EV-to-Revenue | 5.11 | ||
| PEG Ratio | 0.53 | ||
| Shiller PE Ratio | 60.36 | ||
| Current Ratio | 4.47 | ||
| Quick Ratio | 3.67 | ||
| Days Inventory | 784.65 | ||
| Days Sales Outstanding | 122.01 | ||
| Days Payable | 183.47 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -1.40 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.15 | ||
| Price-to-Projected-FCF | 1.90 | ||
| Price-to-Median-PS-Value | 0.58 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.63 | ||
| Price-to-Graham-Number | 1.70 | ||
| Earnings Yield (Joel Greenblatt) % | 7.52 | ||
| Forward Rate of Return (Yacktman) % | 22.54 |
More Statistics
| Revenue (TTM) (Mil) $ | 6,710.8 |
| EPS (TTM) $ | 21.3 |
| Beta | 1.13 |
| Volatility % | 33.7 |
| 52-Week Range $ | 281.89 - 442 |
| Shares Outstanding (Mil) | 109.28 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |